Vistagen Therapeutics Inc (VTGN)

Mar 4, 2025, 8:30 AM EST - 5 days ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Feb 20, 2025, 8:30 AM EST - 17 days ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 6:19 PM EST - 22 days ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 13, 2025, 8:47 PM EST - 23 days ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 4:30 PM EST - 23 days ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 4 weeks ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 4 weeks ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 7 weeks ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 2 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 14, 2024, 8:30 AM EST - 4 months ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 10, 2024, 7:43 AM EST - 4 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:20 PM EST - 4 months ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 5, 2024, 8:30 AM EST - 4 months ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 1, 2024, 8:30 AM EDT - 4 months ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Oct 15, 2024, 7:25 AM EDT - 5 months ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 9, 2024, 8:30 AM EDT - 5 months ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Sep 23, 2024, 8:30 AM EDT - 5 months ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Aug 13, 2024, 7:05 PM EDT - 7 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 4:21 PM EDT - 7 months ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 6, 2024, 8:30 AM EDT - 7 months ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Jul 9, 2024, 8:30 AM EDT - 8 months ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jun 27, 2024, 8:30 AM EDT - 9 months ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 11, 2024, 6:41 PM EDT - 9 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 4:20 PM EDT - 9 months ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Jun 7, 2024, 8:30 AM EDT - 9 months ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

May 29, 2024, 8:30 AM EDT - 10 months ago

Vistagen to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 7, 2024, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 25, 2024, 8:30 AM EDT - 11 months ago

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Apr 9, 2024, 8:30 AM EDT - 11 months ago

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Mar 20, 2024, 9:01 PM EDT - 1 year ago

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Mar 17, 2024, 3:07 AM EDT - 1 year ago

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY BTMD DARE

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at Stifel 2024 Virtual CNS Days

Feb 28, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Feb 13, 2024, 6:34 PM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript

Feb 13, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Feb 6, 2024, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Dec 27, 2023, 8:30 AM EST - 1 year ago

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Dec 22, 2023, 6:24 PM EST - 1 year ago

VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond

Nov 10, 2023, 10:12 AM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript

Nov 9, 2023, 4:30 PM EST - 1 year ago

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 1 year ago

Vistagen to Present at Stifel 2023 Healthcare Conference

Nov 7, 2023, 8:30 AM EST - 1 year ago

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

Nov 6, 2023, 8:00 AM EST - 1 year ago

Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

Oct 5, 2023, 8:30 AM EDT - 1 year ago

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 2, 2023, 7:30 AM EDT - 1 year ago

Vistagen Announces Pricing of $100 Million Underwritten Offering

Sep 12, 2023, 8:30 AM EDT - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Sep 5, 2023, 9:00 AM EDT - 1 year ago

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan